The forecasted mortality rate for prostate malignant neoplasms in the US is expected to gradually increase from 2024 to 2028, starting at 20.5 male deaths per hundred thousand men in 2024 and reaching 20.8 by 2028. This represents a slight but consistent year-on-year increase of approximately 0.5% yearly over this period.
Future trends to watch include advancements in treatment options, early diagnosis techniques, and the impact of healthcare policies aimed at reducing cancer mortality rates. The potential influence of lifestyle changes and public health initiatives on prostate cancer outcomes will also be crucial to monitor.
